Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 7/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910384 | 0.88 | KCNH2 (0.44) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850859 | 0.88 | KCNH2 (0.44) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850835 | 0.88 | KCNH2 (0.44) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850814 | 0.87 | CYP1A2 (0.41) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL4300323 | 0.84 | CYP1A2 (0.43) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850866 | 0.83 | CYP1A2 (0.40) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850834 | 0.82 | KCNH2 (0.41) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850844 | 0.80 | KCNH2 (0.42) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL15850926 | 0.79 | CYP1A2 (0.46) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL910574 | 0.79 | CYP1A2 (0.39) | KCNH2CYP1A2CYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182973-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027249-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-8952010-B2 | Amino group-containing pyrrolidinone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2300477-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300476-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2137196-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141399-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008128942-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187542-A1 | AMINO GROUP-CONTAINING PYRROLIDINONE DERIVATIVE | AR, RCC2, NR3C2 | P2RX3 4851/4885KCNH2 2218/4885CYP1A2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.